Anacor Pharma (NASDAQ: ANAC) reported Q4 EPS of ($0.43), $0.13 worse than the analyst estimate of ($0.30). Revenue for the quarter came in at $21.2 million versus the consensus estimate of $27.93 million.

For earnings history and earnings-related data on Anacor Pharma (ANAC) click here.